iScience,
Journal Year:
2023,
Volume and Issue:
26(10), P. 107952 - 107952
Published: Sept. 19, 2023
Ovarian
cancer
(OC)
is
highly
lethal
due
to
late
detection
and
frequent
recurrence.
Initial
treatments,
comprising
surgery
chemotherapy,
lead
disease
remission
but
are
invariably
associated
with
subsequent
relapse.
The
identification
of
novel
therapies
an
improved
understanding
the
molecular
cellular
characteristics
OC
urgently
needed.
Here,
we
conducted
a
comprehensive
analysis
primary
tumor
cells
their
microenvironment
from
16
chemonaive
10
recurrent
patient
samples.
Profiling
biomarkers
allowed
for
potential
targets
developing
immunotherapies,
while
profiling
yielded
insights
into
its
composition
property
changes
between
Notably,
identified
CD1d
as
biomarker
demonstrated
targeting
by
invariant
natural
killer
T
(iNKT)
cells.
Overall,
our
study
presents
immuno-profiling
during
progression,
guiding
development
immunotherapies
treatment,
especially
disease.
Journal of Inflammation Research,
Journal Year:
2025,
Volume and Issue:
Volume 18, P. 895 - 909
Published: Jan. 1, 2025
Ovarian
cancer
(OC)
remains
one
of
the
most
lethal
gynecological
malignancies,
largely
due
to
its
late-stage
diagnosis
and
high
recurrence
rates.
Chronic
inflammation
is
a
critical
driver
OC
progression,
contributing
immune
evasion,
tumor
growth,
metastasis.
Inflammatory
cytokines,
including
IL-6,
TNF-α,
IL-8,
as
well
key
signaling
pathways
such
nuclear
factor
kappa
B
(NF-kB)
signal
transducer
activator
transcription
3
(STAT3),
are
upregulated
in
OC,
promoting
tumor-promoting
environment.
The
microenvironment
(TME)
characterized
by
cells
like
tumor-associated
macrophages
(TAMs)
regulatory
T
(Tregs),
which
suppress
anti-tumor
responses,
facilitating
evasion.
Furthermore,
utilize
checkpoint
pathways,
PD-1/PD-L1,
inhibit
cytotoxic
cell
activity.
Targeting
these
inflammatory
evasion
mechanisms
offers
promising
therapeutic
strategies.
COX-2
inhibitors,
Janus
kinase/signal
(JAK/STAT)
pathway
blockers,
NF-kB
inhibitors
have
shown
potential
preclinical
studies,
while
targeting
PD-1/PD-L1
CTLA-4
been
explored
with
mixed
results
OC.
Additionally,
emerging
research
on
microbiome
inflammation-related
biomarkers,
microRNAs
(miRNAs)
exosomes,
points
new
opportunities
for
early
detection
precision
medicine.
Future
approaches
treatment
must
focus
personalized
strategies
that
target
TME,
integrating
anti-inflammatory
therapies
immunotherapy
enhance
patient
outcomes.
Continued
into
interplay
between
essential
developing
effective,
long-lasting
treatments.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 14, 2023
Tumor-associated
macrophages
(TAMs)
are
integral
to
the
tumor
microenvironment
(TME),
influencing
cancer
progression
significantly.
Attracted
by
cell
signals,
TAMs
exhibit
unparalleled
adaptability,
aligning
with
dynamic
milieu.
Their
roles
span
from
promoting
growth
and
angiogenesis
modulating
metastasis.
While
substantial
research
has
explored
fundamentals
of
TAMs,
comprehending
their
adaptive
behavior,
leveraging
it
for
novel
treatments
remains
challenging.
This
review
delves
into
TAM
polarization,
metabolic
shifts,
complex
orchestration
cytokines
chemokines
determining
functions.
We
highlight
complexities
TAM-targeted
focusing
on
adaptability
potential
variability
in
therapeutic
outcomes.
Moreover,
we
discuss
synergy
integrating
TAM-focused
strategies
established
treatments,
such
as
chemotherapy,
immunotherapy.
Emphasis
is
laid
pioneering
methods
like
reprogramming
immunotherapy
adoption
single-cell
technologies
precision
intervention.
synthesis
seeks
shed
light
TAMs’
multifaceted
cancer,
pinpointing
prospective
pathways
transformative
enhancing
modalities
oncology.
Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(7), P. 3826 - 3844
Published: July 1, 2024
The
tumor
microenvironment
(TME)
in
ovarian
cancer
(OC)
has
much
greater
complexity
than
previously
understood.
In
response
to
aggressive
pro-angiogenic
stimulus,
blood
vessels
form
rapidly
and
are
dysfunctional,
resulting
poor
perfusion,
tissue
hypoxia,
leakiness,
which
leads
increased
interstitial
fluid
pressure
(IFP).
Decreased
perfusion
high
IFP
significantly
inhibit
the
uptake
of
therapies
into
tumor.
Within
TME,
there
numerous
inhibitor
cells,
such
as
myeloid-derived
suppressor
cells
(MDSCs),
association
macrophages
(TAMs),
regulatory
T
(Tregs),
cancer-associated
fibroblasts
(CAFs)
that
secrete
numbers
immunosuppressive
cytokines.
This
environment
is
thought
contribute
lack
success
immunotherapies
immune
checkpoint
(ICI)
treatment.
review
discusses
components
TME
OC,
how
these
characteristics
impede
therapeutic
efficacy,
some
strategies
alleviate
this
inhibition.
Non-coding RNA Research,
Journal Year:
2024,
Volume and Issue:
9(3), P. 887 - 900
Published: April 4, 2024
In
the
intricate
field
of
cancer
biology,
researchers
are
increasingly
intrigued
by
emerging
role
exosomal
long
non-coding
RNAs
(lncRNAs)
due
to
their
multifaceted
interactions,
complex
modulation
mechanisms,
and
potential
therapeutic
applications.
These
lncRNAs,
carried
within
extracellular
vesicles,
play
a
vital
partin
tumorigenesis
disease
progression
facilitating
communication
networks
between
tumor
cells
local
microenvironment,
making
them
an
ideal
candidates
for
use
in
liquid
biopsy
approach.
However,
lncRNAs
remain
understudied
area,
especially
biology.
Therefore
this
review
aims
comprehensively
explore
dynamic
interplay
various
cellular
components,
including
interactions
with
tumor-stroma,
immune
modulation,
drug
resistance
mechanisms.
Understanding
regulatory
functions
these
processes
can
potentially
unveil
novel
diagnostic
markers
targets
cancer.
Additionally,
emergence
RNA-based
therapeutics
presents
exciting
opportunities
targeting
offering
innovative
strategies
combat
improve
treatment
outcomes.
Thus,
provides
insights
into
current
understanding
highlighting
crucial
roles,
evolving
landscape
interventions.
Furthermore,
we
have
also
discussed
advantage
exosomes
as
carriers
development
personalized
targeted
therapy
patients.
Journal of Advanced Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Feb. 1, 2024
Lipid
metabolism
has
been
implicated
in
a
variety
of
normal
cellular
processes
and
strongly
related
to
the
development
multiple
diseases,
including
tumor.
Tumor-associated
macrophage
(TAM)
emerged
as
crucial
regulator
tumorigenesis
promising
target
for
tumor
treatment.
Molecular Medicine,
Journal Year:
2025,
Volume and Issue:
31(1)
Published: Jan. 8, 2025
Abstract
Background
Predictive,
preventive,
and
personalized
medicine
(PPPM/3PM)
is
a
strategy
aimed
at
improving
the
prognosis
of
cancer,
programmed
cell
death
(PCD)
increasingly
recognized
as
potential
target
in
cancer
therapy
prognosis.
However,
PCD-based
predictive
model
for
serous
ovarian
carcinoma
(SOC)
lacking.
In
present
study,
we
to
establish
index
(CDI)–based
using
PCD-related
genes.
Methods
We
included
1254
genes
from
12
PCD
patterns
our
analysis.
Differentially
expressed
(DEGs)
Cancer
Genome
Atlas
(TCGA)
Genotype-Tissue
Expression
(GTEx)
were
screened.
Subsequently,
14
PCD-gene-based
CDI
model.
Genomics,
single-cell
transcriptomes,
bulk
spatial
clinical
information
TCGA-OV,
GSE26193,
GSE63885,
GSE140082
collected
analyzed
verify
prediction
Results
The
was
an
independent
prognostic
risk
factor
patients
with
SOC.
Patients
SOC
high
had
lower
survival
rates
poorer
prognoses
than
those
low
CDI.
Specific
parameters
combined
nomogram
that
accurately
assessed
patient
survival.
used
PCD-genes
observe
differences
between
groups.
results
showed
immunosuppression
hardly
benefited
immunotherapy;
therefore,
trametinib_1372
BMS-754807
may
be
therapeutic
agents
these
patients.
Conclusions
CDI-based
model,
which
established
genes,
predicted
tumor
microenvironment,
immunotherapy
response,
drug
sensitivity
Thus
this
help
improve
diagnostic
efficacy
PPPM.